Vifor Pharma: Targets Acquisitions As Pure-Play Strategy Delivers
Switzerland’s leader in iron deficiency therapies wants to add new products in this and adjacent therapeutic areas, as strong revenue growth in 2018 backs its strategy of concentrating its efforts on the pharmaceuticals business.
You may also be interested in...
ChemoCentryx gets US approval of Tavneos for ANCA vasculitis, which it says may gradually ramp up to a blockbuster revenue opportunity. Current steroid-heavy standard of care has many drawbacks.
Cara Therapeutics and licensee Vifor Pharma have released positive topline data from the KALM-2 study in chronic kidney disease patients with moderate-to-severe pruritus undergoing hemodialysis, using a first-in-class selective kappa opioid receptor agonist which does not enter the CNS.
The company and partner Vifor said the selective complement 5a receptor inhibitor met both primary and multiple secondary endpoints; US and EU filings are planned for 2020.